Evidence map›Paper›PMID 32558014›Full record

ArticleHuman brain mapping2020

Imaging genomics discovery of a new risk variant for Alzheimer's disease in the postsynaptic SHARPIN gene.

Sourena Soheili-Nezhad, Neda Jahanshad, Sebastian Guelfi, Reza Khosrowabadi, Andrew J Saykin, Paul M Thompson, Christian F Beckmann, Emma Sprooten, Mojtaba Zarei, Alzheimer's Disease Neuroimaging

Open access · goldAbstract read
In one paragraph

Article in Human brain mapping, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Multivariate Analysis and Modelling of multiple Brain endOphenotypes: Let's MAMBO!Computational and structural biotechnology journal · 2021
    Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 4 countries.

Sourena Soheili-NezhadInstitute of Medical Science and Technology, Shahid Beheshti University, Tehran, Iran.ORCID 0000-0002-3571-1270
Neda JahanshadImaging Genetics Center, USC Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Marina del Rey, California, USA.
Sebastian GuelfiReta Lila Weston Research Laboratories, Department of Molecular Neuroscience, University College London (UCL) Institute of Neurology, London, UK.
Reza KhosrowabadiInstitute for Cognitive and Brain Science, Shahid Beheshti University, Tehran, Iran.
Andrew J SaykinCenter for Neuroimaging, Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0002-1376-8532
Paul M ThompsonImaging Genetics Center, USC Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Marina del Rey, California, USA.
Christian F BeckmannDonders Institute for Brain, Cognition and Behaviour, Department of Cognitive Neuroscience, Radboud University Medical Centre, Nijmegen, The Netherlands.
Emma SprootenDonders Institute for Brain, Cognition and Behaviour, Department of Cognitive Neuroscience, Radboud University Medical Centre, Nijmegen, The Netherlands.
Mojtaba ZareiInstitute of Medical Science and Technology, Shahid Beheshti University, Tehran, Iran.
Alzheimer's Disease Neuroimaging
Radboud University Nijmegen · NLUniversity of Southern California · USIndiana University School of MedicineInstitute for Cognitive Science Studies · IRInstitute of Structural and Molecular Biology · GBShahid Beheshti University · IR

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Deconstructing and challenging TDP-43 proteinopathies: from FTLD/ALS to Alzheimer's diseaseR01AG059871 · NIA · UNIVERSITY OF FLORIDA · PI RINCON-LIMAS, DIEGO E · 2018 to 2022
$1.9M
ENIGMA World Aging CenterR56AG058854 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI THOMPSON, PAUL M · 2018 to 2018
$683k
Biogen PO 969323NIA NIH HHS R01 AG059871NIA NIH HHS R56 AG058854NIA NIH HHS U01 AG024904Radboud Universitair Medisch Centrum R0003664
6 · The paper itself

Abstract

Molecular mechanisms underlying Alzheimer's disease (AD) are difficult to investigate, partly because diagnosis lags behind the insidious pathological processes. Therefore, identifying AD neuroimaging markers and their genetic modifiers may help study early mechanisms of neurodegeneration. We aimed to identify brain regions of the highest vulnerability to AD using a data-driven search in the AD Neuroimaging Initiative (ADNI, n = 1,100 subjects), and further explored genetic variants affecting this critical brain trait using both ADNI and the younger UK Biobank cohort (n = 8,428 subjects). Tensor-Based Morphometry (TBM) and Independent Component Analysis (ICA) identified the limbic system and its interconnecting white-matter as the most AD-vulnerable brain feature. Whole-genome analysis revealed a common variant in SHARPIN that was associated with this imaging feature (rs34173062, p = 2.1 × 10

Indexed as

Imaging GenomicsNeuroimagingAgedAged, 80 and overAlzheimer DiseaseCognitive DysfunctionCross-Sectional StudiesEntorhinal CortexFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansLimbic SystemLongitudinal StudiesMagnetic Resonance ImagingMaleSHARPIN protein, humanUbiquitinsAlzheimer's diseasebrain atrophyindependent component analysissynaptic adhesiontensor-based morphometrywhole-genome sequencing

Identifiers

PMID32558014
PMCPMC7416020
OpenAlexW3036950375

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.